Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (IgG-IgG) (BSIG-H223)

Anti-CD2 x Anti-TCR (Vβ8) Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-CD2 and anti-TCR (Vβ8) parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can activate T cells. It is designed for the research of Tumors therapy.

Datasheet

Specifications

Targets

CD2 & TCR (Vβ8)

Type

IgG-IgG

Species Reactivity

Mouse

Target 1

CD2

Host Animal 1

Human

Target 2

TCR (Vβ8)

Host Animal 2

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Tumors

Targets

Target 1

CD2

Gene ID

12481

UniProt ID

P06729

Alternative Names

CD2; CD2 molecule; T11; SRBC; LFA-2; T-cell surface antigen CD2; leukocyte function-associated antigen-2; LFA-3 receptor; rosette receptor; erythrocyte receptor; lymphocyte-function antigen-2; T-cell surface antigen T11/Leu-5; CD2 antigen (p50), sheep red blood cell receptor

Target 2

TCR (Vβ8)

Gene ID

100124664

Alternative Names

Trbv8; T cell receptor beta variable 8; TCR; T-cell receptor

Welcome! For price inquiries, we will get back to you as soon as possible.

To order, please email

INQUIRY

Online Inquiry

45-1 Ramsey Road, Shirley, NY 11967, USA
Email:
Fax: 1-631-207-8356
Or Call
Tel: 1-631-381-2994